Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Crossref DOI link: https://doi.org/10.1007/s12325-019-01082-6
Published Online: 2019-09-09
Published Print: 2019-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Glassberg, Marilyn K.
Nathan, Steven D.
Lin, Chin-Yu
Morgenthien, Elizabeth A.
Stauffer, John L.
Chou, Willis
Noble, Paul W.
Text and Data Mining valid from 2019-09-09
Version of Record valid from 2019-09-09
Article History
First Online: 9 September 2019